(MGTA) – Business Wire
-
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
-
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
-
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference
-
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
-
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
-
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
-
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
-
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
-
Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
-
Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
-
Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
-
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
-
Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
-
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
-
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
-
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
-
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clini
-
Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
-
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
-
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
-
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
-
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
-
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
-
Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference
-
Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marr
-
Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
-
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (
-
Anne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech’s Board of Directors and Chair of the Audit Committee
-
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
-
Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditionin
-
Magenta Therapeutics and bluebird bio Announce a Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Ce
-
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer
-
Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results
-
Magenta Therapeutics Announces Multiple Presentations Across Stem Cell Transplant Portfolio at The American Society of Hematology (ASH) Annual Meeting
-
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in September
-
Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene Editing Approaches to Cure HIV
-
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality; Announces Transition of Jason Ryan, Chief Operati
-
Magenta Therapeutics Announced It Will Present Clinical and Pre-Clinical Data from Across Immune and Blood System Reset Portfolio at European Society for Blood and Marrow Transplantation (EBMT) Annual
-
Magenta Therapeutics Reports Recent Business Highlights and Second Quarter Financial Results
-
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
-
Magenta Therapeutics Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Magenta Therapeutics Announces Pricing of Public Offering
-
Magenta Therapeutics Launches Proposed Public Offering
-
Magenta Therapeutics and Beam Therapeutics Announce Collaboration to Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 as Conditioning Regimen for Base Editing Therapies
-
Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones
-
Magenta Therapeutics Announces Collaboration with the National Marrow Donor Program/Be The Match to Advance Development of MGTA-145 for First-Line Mobilization of Stem Cells from Healthy Donors and Su
Back to MGTA Stock Lookup
